Irving News:
Irving’s Criminal Alien Program Recognized by U.S. Congressman Pete Sessions Archive
Posted: 6/4/2007
U.S. Congressman Pete Sessions visited the Irving Police Department on May 29 to recognize the City of Irving for its cooperation with Immigration and Customs Enforcement (ICE) through Irving’s Criminal Alien Program.
The Police Department initiated an arrangement with ICE in September in which an ICE agent would visit the Irving Jail up to five times per week to determine the residency status of prisoners. This resulted in an average of 40 to 50 illegal alien detentions in a two-week period.
A new process with the Detention and Removal Division of ICE was implemented in April after ICE indicated that their agents would no longer be available for daily jail visits. Residency status is now reviewed over the phone by the Detention and Removal Division. ICE is now able to determine residency status 24 hours a day, seven days a week, which has increased the number of illegal aliens identified by nearly three times the amount identified during the average week under the previous method.
“I would like to take this opportunity to say thanks to Chief Larry Boyd and the City of Irving for their successful implementation of this program,” said Sessions. “This new method ensures that law-abiding residents are safe through the identification and deportation of these illegal criminals. It’s time we focus our resources on these criminals and deal with them on a federal level.”
Mayor Herbert Gears added, “Irving is a model community for other cities, and as we utilize the programs offered by our federal government, we will continue making strides toward maintaining the safety of our residents. Together, we are getting results.”
Emergency care trial part of new strategy to save lives of heart attack victims Living in Irving
Posted: 5/18/2007
UT Southwestern Medical Center and several area communities are involved in a research study testing whether or not a new intravenous solution can reduce heart attack complications and death.
Some patients will receive the research solution – a mixture of glucose, insulin and potassium – when they are treated by paramedics at the site of the heart attack or in the ambulance.
The IMMEDIATE (Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care) Trial in the Irving area begins on May 21st. Research will also be conducted in Wisconsin and Massachusetts. Enrollment in the Dallas area will last about two years. In all, 15,450 patients will be enrolled.
Dr. James Atkins, professor of internal medicine and emergency medicine and director of the Emergency Medicine Education Program at UT Southwestern, is the principal investigator for Texas.
“When you’re having a heart attack, time is very critical,” said Dr. Atkins. “The faster you act, the more heart muscle can be saved and the lower the death rate."
During on-site care or transportation, patients 30 years of age and older with symptoms of a threatened or established heart attack will be told of the IMMEDIATE study and, if they agree to participate, will receive either a standard intravenous solution of glucose and water or a solution of glucose, insulin and potassium, also known as GIK. Informed consent will be obtained as soon as feasible after arrival at the emergency department.
Each enrolled patient will be randomly assigned the GIK solution, the effectiveness of which is being tested, or the standard solution, which patients now receive. Neither the patient nor the EMS staff will know which solution is administered.
Once the patient arrives at the hospital, emergency department physicians at Baylor Medical Center at Irving and the Las Colinas Medical Center will confirm the diagnosis and continue the administration of the standard glucose and water solution or the GIK solution for 12 hours, with follow-up phone consultations planned at three, six and 12 months.
“We’re very interested in studying strategies that slow down death of muscle and widen the window that we can treat the patient,” said Dr. Atkins.
A heart attack occurs when a clot blocks blood flow in the coronary arteries to the heart muscle. Immediate GIK treatment may potentially protect the heart muscle that is not receiving sufficient blood flow. Previous studies suggest that administering GIK during a heart attack may reduce irregular heartbeats and slow the progression and limit the scope of the heart attack.
This year, about 1.2 million Americans will have a first or recurrent heart attack and about 500,000 of them will die, according to the American Heart Association. Heart disease is the nation’s single leading cause of death.
The IMMEDIATE trial is funded by a $36 million grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health. It is overseen by the Center for Cardiovascular Health Services Research at Tufts-New England Medical Center.
Emergency Care Trial Part of New Strategy to Save Lives of Heart Attack Victims Living in Irving
Posted: 5/18/2007
UT Southwestern Medical Center and several area communities are involved in a research study testing whether or not a new intravenous solution can reduce heart attack complications and death.
Some patients will receive the research solution – a mixture of glucose, insulin and potassium – when they are treated by paramedics at the site of the heart attack or in the ambulance.
The IMMEDIATE (Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care) Trial in the Irving area begins on May 21st. Research will also be conducted in Wisconsin and Massachusetts. Enrollment in the Dallas area will last about two years. In all, 15,450 patients will be enrolled.
Dr. James Atkins, professor of internal medicine and emergency medicine and director of the Emergency Medicine Education Program at UT Southwestern, is the principal investigator for Texas.
“When you’re having a heart attack, time is very critical,” said Dr. Atkins. “The faster you act, the more heart muscle can be saved and the lower the death rate."
During on-site care or transportation, patients 30 years of age and older with symptoms of a threatened or established heart attack will be told of the IMMEDIATE study and, if they agree to participate, will receive either a standard intravenous solution of glucose and water or a solution of glucose, insulin and potassium, also known as GIK. Informed consent will be obtained as soon as feasible after arrival at the emergency department.
Each enrolled patient will be randomly assigned the GIK solution, the effectiveness of which is being tested, or the standard solution, which patients now receive. Neither the patient nor the EMS staff will know which solution is administered.
Once the patient arrives at the hospital, emergency department physicians at Baylor Medical Center at Irving and the Las Colinas Medical Center will confirm the diagnosis and continue the administration of the standard glucose and water solution or the GIK solution for 12 hours, with follow-up phone consultations planned at three, six and 12 months.
“We’re very interested in studying strategies that slow down death of muscle and widen the window that we can treat the patient,” said Dr. Atkins.
A heart attack occurs when a clot blocks blood flow in the coronary arteries to the heart muscle. Immediate GIK treatment may potentially protect the heart muscle that is not receiving sufficient blood flow. Previous studies suggest that administering GIK during a heart attack may reduce irregular heartbeats and slow the progression and limit the scope of the heart attack.
This year, about 1.2 million Americans will have a first or recurrent heart attack and about 500,000 of them will die, according to the American Heart Association. Heart disease is the nation’s single leading cause of death.
The IMMEDIATE trial is funded by a $36 million grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health. It is overseen by the Center for Cardiovascular Health Services Research at Tufts-New England Medical Center.
|
